Cambridge, MA, November 29, 2009 - Intelligent Medical Devices, Inc. (IMDx) announced the issuance of U.S. Patent No. 7,622,250 entitled “Clinically Intelligent Diagnostic Devices and Methods”. A multiplexed method for determining the effectiveness and suitability of therapeutic agents to treat one or more symptoms of medical condition(s) in an individual is described.
The patented methods enable detection of the presence of a genetic sequence indicative of a target(s) for causes of medical symptoms that require treatment. The methods can also be used to detect the presence or absence of genetic markers that define an individual’s tolerance, resistance, intolerance, or susceptibility to a therapeutic agent. These new methods and associated devices allow for the inclusion of additional tests to existing assays. This flexibility is crucial for creating and maintaining state of the art tests.
About IMDx
Based in Cambridge, MA, IMDx (www.IntelligentMDx.com) is an innovative company that designs, develops and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and competitively differentiated for a range of disease areas for current and next generation systems, including targets in infectious diseases, oncology and genetics. IMDx's expertise spans evolutionary biology, bioinformatics, microbiology, chemistry and molecular biology. These capabilities are harnessed by IMDx's proprietary bioinformatics and product development processes allowing for the rapid design and development of tests to meet clinical needs.
For more information, please contact Sarah Toomey at +1-617-871-6431 or stoomey@intelligentmdx.com